Celldex Therapeutics Stock Price

0.27 (2.22%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Celldex Therapeutics Inc CLDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.27 2.22% 12.42 11.90 12.72 12.09 12.15 14:14:18
Bid Price Ask Price Spread Spread % News
12.41 12.46 0.05 0.4% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,637 372,169 $ 12.40 $ 4,615,850 5,234,170 1.50 - 13.93
Last Trade Time Type Quantity Stock Price Currency
14:14:23 25 $ 12.435 USD

Celldex Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 482.24M 38.83M 38.81M $ 3.57M $ - -3.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Celldex Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CLDX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week13.6413.878511.750112.44629,708-1.22-8.94%
1 Month4.4213.934.29019.736,552,2018.00181.0%
3 Months1.9313.931.878.142,944,28510.49543.52%
6 Months2.5913.931.507.511,516,0799.83379.54%
1 Year2.7113.931.507.05814,7499.71358.3%
3 Years2.5113.930.172.421,435,1349.91394.82%
5 Years24.6828.080.174.571,750,966-12.26-49.68%

Celldex Therapeutics Description

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.